Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
The 26th Congress of the European Hematology Association (EHA) 2021, 9-17 June, will see leading experts from around the globe gather virtually for a fantastic demonstration of the most ground-breaking research in the field of hematology.
Exciting data on promising biomarkers, CAR T-cell and NK-cell therapy, transplant research, novel drugs and more will be showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalessemia, and beyond.
EHA 2021
#ASH23 a great opportunity to discuss with colleagues from #Armenia about the development of clinical research in hematology in Yerevan @NersesGH Prof. Y. Hakobyan #ArmenianHematologyAssociation
#ASH23 HOVON analysis of dynamic frailty in #MMsm - building on work by @HiraSMian @tanyawildes et al.
Some pts get less frail with myeloma treatment đź‘Ź
Also note that, of pts who become “frailer,” some of this is artifactual because IMWG model de facto penalizes older age.
Great chatting with @tarekmd91 (@IcahnMountSinai) who gave an overview of updates on the use of #CART in #MultipleMyeloma
@ASH_hematology #Myeloma #MMsm #HemOnc
#ASH23 | We spoke with @NersesGH from Yeolyan Hematology and Oncology Center on challenges that remain in the diagnosis and treatment of #BPDCN
@ASH_hematology #HemOnc
Head to poster number 1861 at #ASH23 at 5:30 pm to learn more!
@Daver_Leukemia
@doctorpemm
@DrHKantarjian
@MDAndersonNews
#leusm
#mpnsm
EHA 2021
The 26th Congress of the European Hematology Association (EHA) 2021, 9-17 June, will see leading experts from around the globe gather virtually for a fantastic demonstration of the most ground-breaking research in the field of hematology.
Exciting data on promising biomarkers, CAR T-cell and NK-cell therapy, transplant research, novel drugs and more will be showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalessemia, and beyond.
#ASH23 a great opportunity to discuss with colleagues from #Armenia about the development of clinical research in hematology in Yerevan @NersesGH Prof. Y. Hakobyan #ArmenianHematologyAssociation
#ASH23 HOVON analysis of dynamic frailty in #MMsm - building on work by @HiraSMian @tanyawildes et al.
Some pts get less frail with myeloma treatment đź‘Ź
Also note that, of pts who become “frailer,” some of this is artifactual because IMWG model de facto penalizes older age.
Great chatting with @tarekmd91 (@IcahnMountSinai) who gave an overview of updates on the use of #CART in #MultipleMyeloma
@ASH_hematology #Myeloma #MMsm #HemOnc
#ASH23 | We spoke with @NersesGH from Yeolyan Hematology and Oncology Center on challenges that remain in the diagnosis and treatment of #BPDCN
@ASH_hematology #HemOnc
Head to poster number 1861 at #ASH23 at 5:30 pm to learn more!
@Daver_Leukemia
@doctorpemm
@DrHKantarjian
@MDAndersonNews
#leusm
#mpnsm
